SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

SMARCA4 is commonly inactivated in lung and ovarian cancers. Here the authors show that SMARCA4-deficient tumours have significantly reduced levels of the histone demethylases KDM6s and a strong dependency on these demethylases for tumour growth, so that they are vulnerable to KDM6s inhibition.

Xehetasun bibliografikoak
Egile Nagusiak: Octavio A. Romero, Andrea Vilarrubi, Juan J. Alburquerque-Bejar, Antonio Gomez, Alvaro Andrades, Deborah Trastulli, Eva Pros, Fernando Setien, Sara Verdura, Lourdes Farré, Juan F. Martín-Tejera, Paula Llabata, Ana Oaknin, Maria Saigi, Josep M. Piulats, Xavier Matias-Guiu, Pedro P. Medina, August Vidal, Alberto Villanueva, Montse Sanchez-Cespedes
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Nature Portfolio 2021-07-01
Saila:Nature Communications
Sarrera elektronikoa:https://doi.org/10.1038/s41467-021-24618-3

Internet

https://doi.org/10.1038/s41467-021-24618-3

Antzeko izenburuak